AbbVie Psoriatic Arthritis Drug Shows Long-term Effect On Skin, Joint Symptoms
AbbVie Inc (NASDAQ: ABBV) announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials of Skyrizi (risankizumab) in active psoriatic arthritis.
Results showed that at week 100 of the open-label extension period, patients receiving SKYRIZI reported improvement in skin and joint symptoms, with more than half of patients in KEEPsAKE 1 and 2 achieving a 90% reduction in the Psoriasis Area and Severity Index (PASI 90).
Additionally, the data demonstrated no new observed safety signals through 100 weeks.
At week 100, pooled results showed that 76% and 57% of patients, respectively, initially treated with Skyrizi, achieved resolution of dactylitis and enthesitis.
Skyriszi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
Price Action: ABBV shares are up 0.85% at $142.62 on the last check Monday.
See more from Benzinga
Some Breast Implant Cases Are Associated With Skin Cancer, FDA Receives Reports
Ironwood's Constipation Drug Shows Efficacy In Pediatric Patients
Digital World Acq (NASDAQ:DWAC) – Trump Lawyer Seeks To Avoid Criminal Prosecution In Mar-A-Lago Case — B
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.